Key Takeaways Zimmer Biomet's growth is driven by knee segment strength and expanding cementless implant adoption.ZBH boosted innovation via Monogram acquisition and robotics, with commercialization eyed for 2027.High debt levels and intense competition remain ZBH's key challenges despite stable market conditions.Zimmer Biomet (ZBH) appears well-positioned for growth in the coming quarters, supported by the continued execution of its market strategies centered on People and Culture, Operational Excellence, ...

BTIG downgraded Zimmer Biomet (NYSE: ZBH) to Neutral from Buy and withdrew its $112 price target, citing limited upside potential in the near term. The firm noted that fiscal 2025 was a challenging year for the company, with shares declining 14.8% despite efforts to improve both growth and profitability. BTIG said that recently launched products, including the so-called “Magnificent 7,” did not significantly accelerate organic growth during 2025, while Paragon 28 also underperformed expectations. The downgr ...

Zimmer Biomet Holdings, Inc. (ZBH) is a leading global medical technology company that specializes in musculoskeletal healthcare solutions, including orthopedic reconstructive implants, sports medicine products, biologics, dental implants, and robotic-assisted surgical technologies used to treat disorders of bones, joints, and supporting soft tissues. Headquartered in Warsaw, Indiana, the company markets its products to hospitals, surgeons, and healthcare providers worldwide through direct sales and distri ...

Core Viewpoint - Zimmer Biomet's recent earnings report shows a mixed performance with adjusted earnings per share beating estimates, while overall revenue growth indicates a positive trend despite some margin contraction [2][4][8]. Financial Performance - The fourth-quarter adjusted earnings per share was $2.42, exceeding the Zacks Consensus Estimate by 1.7% and reflecting a year-over-year increase of 4.8% [2]. - Full-year adjusted earnings per share reached $8.20, marking a 2.5% increase year over year and slightly beating the Zacks Consensus Estimate by 0.5% [3]. - Net sales for the fourth quarter were $2.24 billion, a 10.9% increase year over year, surpassing the Zacks Consensus Estimate by 1.9% [4]. - Full-year net sales totaled $8.23 billion, up 7.2% year over year, also marginally exceeding the Zacks Consensus Estimate by 0.5% [4]. Revenue Breakdown - U.S. sales for the fourth quarter amounted to $1.31 billion, reflecting an 11.11% year-over-year increase, while international sales were $931.2 million, up 10.6% year over year [5]. - Sales in the Knees segment improved by 8.6% year over year to $911 million, while Hips sales grew by 6.8% to $555.4 million. The S.E.T. unit saw a significant rise of 20.1% to $587.6 million [6]. Margin Analysis - Adjusted gross margin was 64.7%, down 632 basis points year over year, primarily due to a 35.1% increase in the cost of products sold [8]. - Selling, general, and administrative expenses rose by 16.8% to $872.3 million, while research and development expenses increased by 9.6% to $118.8 million [8]. - Adjusted operating margin contracted by 821 basis points to 20.5% [8]. Cash Position - At the end of the fourth quarter, cash and cash equivalents stood at $591.9 million, up from $525.5 million at the end of the previous year [9]. - Cumulative net cash provided by operating activities was $1.70 billion, compared to $1.50 billion in the prior year [9]. Future Outlook - For 2026, revenue growth is projected to be between 2.5% and 4.5%, with the Zacks Consensus Estimate for revenues at $8.41 billion, indicating a 3.1% year-over-year growth [10]. - Adjusted earnings per share guidance for the full year is expected to be in the range of $8.30 to $8.45, while the Zacks Consensus Estimate for adjusted earnings per share is pegged at $8.54 [10]. Market Sentiment - Estimates for Zimmer Biomet have trended downward over the past month, indicating a potential shift in market sentiment [11][13]. - The company currently holds a Zacks Rank 3 (Hold), suggesting an expectation of an in-line return in the coming months [13].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Zimmer Biomet Holdings, Inc., and may file a class action on behalf of investors [1][2]. Group 1: Stock Performance and Financial Results - Zimmer's stock price fell by $15.63, or 15.2%, closing at $87.55 per share on November 5, 2025, following the release of its third quarter 2025 financial results [2]. - The company reported net sales of approximately $2 billion for the third quarter of 2025, attributing the results to weaknesses in Latin America, Emerging Markets in Europe, and non-core businesses [2]. - Zimmer lowered the top end of its full-year organic revenue growth forecast from 4.5% to 4.0%, citing a modest slowdown in the U.S. revision market for hips and knees and continued weakness in restorative therapies [2]. Group 2: Legal Actions and Investor Support - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing, with a history of recovering over $5.5 billion for aggrieved investors [2]. - Investors are encouraged to contact the firm for a complimentary case evaluation and to discuss options for recovering losses [1].

Core Insights - Zimmer Biomet will present new clinical and operational data and showcase innovations at the AAOS 2026 Annual Meeting, with Arnold Schwarzenegger as the Presidential Guest Speaker [1] Group 1: Event Details - The AAOS 2026 Annual Meeting will take place on March 5, 2026, featuring a main-stage conversation with Arnold Schwarzenegger, Zimmer Biomet's CEO Ivan Tornos, and AAOS President Ned Amendola [1] - The company aims to highlight its leadership in orthopedic implants and the integration of robotic and digital technologies that enhance surgical outcomes [1] Group 2: Innovations and Technologies - Zimmer Biomet will showcase a variety of orthopedic innovations, including: - Robotics and Navigation Technologies designed to improve surgical precision [1] - OrthoGrid Hip AI®, an AI-powered technology for hip surgeons [1] - Monogram Technologies TKA System, a semi-autonomous robotic technology for total knee arthroplasty [1] - TMINI® Miniature Robotic System for accurate implant placement [1] - ROSA® Knee with OptimiZe™, which offers personalized surgical planning and automated kinematic alignment [1] Group 3: New Data Presentation - New data to be presented includes: - Post-operative gait metrics for assessing joint replacement outcomes [1] - Correlation between 90-day readmissions and post-operative step counts from smart implantable devices [1] - Impact of smart devices on post-operative complications in knee replacements [1] - Relationship between step counts and venous thromboembolisms following TKA [1] - Efficiency improvements in ambulatory surgery centers [1] - Safety and efficacy data for the Oxford® Cementless Partial Knee [1] - Expansion of the Persona® Revision Knee System for personalized knee care [1] Group 4: Additional Innovations - The exhibit will also feature innovations in shoulder reconstruction, sports medicine, trauma, and solutions for infection prevention from the recent Paragon 28 acquisition [1] - Zimmer Biomet's ZBX™ Ambulatory Surgery Center Solutions will be highlighted, providing a comprehensive approach for ASC operations [1]

Sales Performance - In 2025, the company's net sales increased by 7.2% to $8,231.5 million compared to 2024, driven by the acquisition of Paragon 28, market growth, and new product introductions [175]. - The company expects net sales growth of 2.5% to 4.5% in 2026, with the Paragon 28 acquisition contributing an estimated 1.0% to this growth [177]. - In 2025, U.S. net sales grew by 7.3% to $4,764.0 million, with the Paragon 28 acquisition contributing 3.6% to this growth [180]. - International net sales increased by 7.0% to $3,467.5 million in 2025, with foreign currency exchange rates contributing 1.8% to this growth [185]. - The S.E.T. product category saw a significant increase in net sales by 15.2% in 2025, largely due to the Paragon 28 acquisition, which contributed 10.5% to this growth [186]. - Changes in volume and mix of product sales positively impacted year-over-year sales growth by 6.4% in 2025, with the Paragon 28 acquisition contributing 2.5% [182]. Earnings and Expenses - Net earnings for 2025 were $705.1 million, a decline from $903.8 million in 2024, primarily due to inventory charges of approximately $170 million and costs related to acquisitions [176]. - Cost of products sold as a percentage of net sales increased to 30.3% in 2025 from 28.5% in 2024, driven by inventory charges and tariffs [187]. - The company's gross margin decreased to 61.6% in 2025 from 63.8% in 2024, impacted by inventory charges and U.S. tariffs [190]. - Research and development expenses as a percentage of net sales slightly decreased to 5.6% in 2025 from 5.7% in 2024 [187]. - R&D expenses increased in amount but decreased as a percentage of net sales in 2025, driven by Paragon 28-related expenses and higher technology project spending, offset by lower EU Medical Device Regulation compliance costs [191]. - SG&A expenses increased in both amount and percentage of net sales in 2025, primarily due to variable selling and distribution costs, Paragon 28-related expenses, and higher performance-related compensation [192]. - The company recognized $181.2 million in restructuring expenses in 2025, down from $219.0 million in 2024, mainly due to lower costs associated with U.S. and Canada ERP implementation [193]. - Acquisition-related expenses increased in 2025, including $55.1 million for compensation related to Paragon 28 and Monogram acquisitions, partially offset by $77.1 million in net gains from declines in estimated fair values of contingent consideration [194]. Cash Flow and Financial Position - Cash flows from operating activities increased to $1,697.1 million in 2025 from $1,499.4 million in 2024, driven by higher net sales and favorable timing of accounts payable [208]. - Cash flows used in investing activities rose to $1,975.7 million in 2025, including $1,393.2 million for the acquisitions of Paragon 28 and Monogram [209]. - The company had $591.9 million in cash and cash equivalents as of December 31, 2025, with $1.0 billion available under a 364-day revolving credit agreement [206]. Tax and Restructuring - The effective tax rate increased to 15.1% in 2025 from 12.7% in 2024, influenced by foreign rate differentials and intercompany transactions [198]. - The company expects to reduce gross annual pre-tax operating expenses by approximately $175 million by the end of 2027 as part of its restructuring plans [218]. - Management recognized a charge of approximately $170 million to reduce inventory and instruments to their net realizable value due to reduced demand for certain products [225]. Contingent Consideration and Assets - As of December 31, 2025, the company recorded $299.2 million of contingent consideration related to completed business combinations, an increase from $180.7 million in 2024 [237]. - The company had net assets, excluding goodwill and intangible assets, in legal entities with non-U.S. Dollar functional currencies of $1,490.4 million at December 31, 2025 [244]. Risk Management - A sensitivity analysis indicated that a 10 percent change in foreign currency exchange rates could affect earnings by approximately $109 million to $107 million before income taxes [242]. - The majority of the company's debt is fixed-rate, and a 10 percent change in interest rates would not have a material effect on interest expense [250]. - The company is exposed to credit risk primarily from cash and cash equivalents, derivative instruments, and accounts receivable, but believes reserves for losses are adequate [251]. - Management evaluates deferred tax assets on an ongoing basis and provides valuation allowances unless it is "more likely than not" that the deferred tax benefit will be realized [227]. - During the annual goodwill impairment testing in Q4 2025, the estimated fair values of two reporting units exceeded their carrying values by more than 25 percent [232]. - The company enters into supply contracts for raw materials with terms of 12 to 24 months to mitigate commodity price risks [247]. - The company uses derivative financial instruments solely as risk management tools and not for speculative investment purposes [240].

Core Viewpoint - Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (ZBH) due to concerns over the company's "high confidence" assurances regarding its 2025 revenue targets following a 15% stock decline and reduced revenue guidance [1] Group 1: Investigation Focus - The investigation examines whether Zimmer Biomet's senior management misled investors about the stability of its international business, particularly in emerging markets [1] - The firm is looking into potential violations of federal securities laws related to overly optimistic guidance while concealing operational disruptions [1] Group 2: Recent Developments - On November 5, 2025, Zimmer Biomet reported a year-over-year organic revenue growth of only 5%, significantly missing its forecast and reducing its top-line organic revenue growth forecast to 4% [1] - The company disclosed distributor order cancellations in emerging markets, particularly in the Middle East and Eastern Europe, and acknowledged serious headwinds in Latin America [1] - Following these revelations, CEO Ivan Tornos stated the need for more measured external commentary, which contributed to the 15% drop in stock price on the same day [1] Group 3: Previous Assurances - In an August 7, 2025 earnings call, management expressed "very high" confidence in achieving a year-over-year organic revenue growth forecast of 3.5% to 4.5%, attributing it to emerging markets distributor purchases [1] - These optimistic statements led to a 7% increase in the company's share price on that day [1]

Core Viewpoint - Zimmer Biomet Holdings, Inc. has demonstrated strong financial performance in the fourth quarter of 2025 and for the full year, highlighting its strategic focus on growth and shareholder returns. Financial Performance - In Q4 2025, Zimmer Biomet reported net sales of $2.244 billion, a 10.9% increase year-over-year [2] - The company's net earnings for Q4 were $139.3 million, with a gross profit of $785.4 million [2] - For the full year, net sales reached $8.232 billion, reflecting a 7.2% increase from the previous year [3] - Operating cash flow for the year was $1.697 billion, and free cash flow was $1.172 billion [3] Earnings Per Share - Diluted earnings per share decreased by 41.7% to $0.70 in Q4, while adjusted diluted earnings per share increased by 4.8% to $2.42, exceeding estimates of $2.38 [2] Strategic Initiatives - The company has implemented a direct and specialized sales organization in the U.S. to drive long-term growth [2] - A new stock repurchase authorization of up to $1.5 billion has been approved, effective from February 9, 2026, with no expiration date, indicating a commitment to returning capital to shareholders [3] Acquisitions - The acquisition of Paragon 28, Inc. in April 2025 has been excluded from organic constant currency sales calculations to provide a clearer performance picture [4] - The company remains focused on delivering EPS and free cash flow growth, as emphasized by its leadership [4]

Company Overview - Zimmer Biomet Holdings, Inc. (ZBH) has a market cap of $17.8 billion and specializes in orthopedic implants and surgical solutions, with a focus on joint replacement, sports medicine, trauma, spine, and dental applications [1] - The company is headquartered in Warsaw, Indiana, and serves hospitals and surgeons globally, being particularly known for its knee and hip replacement systems and its advancements in robotic-assisted and digital surgery platforms [1] Stock Performance - Over the past year, ZBH stock has underperformed the broader market, declining 9% compared to the S&P 500 Index's 14.4% returns [2] - Year-to-date, ZBH stock has increased by 1.7%, slightly outperforming the S&P 500's 1.4% rise [2] - In comparison to the US Medical Devices Ishares ETF (IHI), which saw a 9.3% dip over the past 52 weeks, ZBH has shown better relative performance [3] Financial Performance - For fiscal 2025 Q4, Zimmer Biomet reported net sales of $2.24 billion, reflecting a year-over-year increase of 10.9%, driven by strong demand for hip and knee implants [6] - Adjusted diluted EPS for Q4 increased by 4.8% to $2.42, exceeding market expectations [6] - For the full year 2025, the company achieved $8.23 billion in revenue and announced a $1.5 billion share repurchase program [6] Future Guidance - Management has provided guidance for 2026, projecting revenue growth of 2.5% to 4.5% and adjusted EPS in the range of $8.30 to $8.45, considering near-term challenges from U.S. sales transformation [7] - Analysts expect ZBH to deliver an adjusted EPS of $8.41 for FY2026, representing a year-over-year increase of 3.1% [7] - The company has a strong earnings surprise history, having exceeded bottom-line estimates in each of the past four quarters [7] Analyst Ratings - Among 26 analysts covering ZBH stock, the consensus rating is a "Hold," which includes seven "Strong Buys," one "Moderate Buy," 15 "Holds," and three "Strong Sells" [8]